Navigation Links
VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
Date:11/12/2007

le inhibitor of 5-LO, which is a key enzyme in the biosynthesis of leukotrienes (important mediators of inflammation involved in the development and progression of atherosclerosis). VIA-2291 is being developed as a once-daily, oral drug to target inflammation in the blood vessel wall, thereby potentially decreasing the risk of major adverse cardiovascular events, including heart attack and stroke. According to the American Heart Association, 15.8 million patients in the U.S. have coronary artery disease.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase II clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.

Forward-Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/13/2014)... December 13, 2014 QuickSTAT is making ... and Cold Chain capabilities, and is delighted to announce ... France, to serve Life Science clients in the region. ... a controlled-ambient warehouse, will provide 24/7 transportation and logistics ... investigational drugs, patient-clinical specimens, API, following IATA rules and ...
(Date:12/13/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/6p4j9m/glucose_sensors ) ... Sensors: the Next Generation" report to their ... The convergence of small-scale electronics and ... a better future to millions of diabetes patients ... levels accurately and reliably have the capability to ...
(Date:12/13/2014)... and SAN ANTONIO , Dec. ... today announced the presentation of data at the San ... EPO-ANE-3010 study evaluating epoetin alfa plus best supportive care ... patients with metastatic breast cancer receiving standard chemotherapy. This ... was to rule out a 15 percent or greater ...
(Date:12/12/2014)... 2014 Graphite Metallizing Corporation, the manufacturer ... and process equipment, has appointed Kirk Staller as Sales ... Canada. Staller holds a B.S. degree from Purdue University ... market place, much of it with a manufacturer of ... Michigan office. , “We are pleased to ...
Breaking Biology Technology:Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2Glucose Sensors: the Next Generation 2Glucose Sensors: the Next Generation 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 2Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 3Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 4Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 5Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 6Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 7Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 8Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 9Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 10Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 11Data from the EPO-ANE-3010 Study Evaluating Epoetin Alfa Presented at San Antonio Breast Cancer Symposium 12Kirk Staller Joins Graphite Metallizing Corporation 2
... Tuesday, July 15 at 4:30 p.m. Eastern -, ... ), a molecular diagnostics company, will host a roundtable,teleconference ... Principal Investigator on the submission and Associate Professor of,Gynecologic ... keynote,speaker of the roundtable., Vermillion,s ovarian tumor triage ...
... LOS ANGELES and LONDON, July 11 Signalife,Inc. ... received board approval to proceed,with its previously-announced merger ... and that a specially-formed committee has been,appointed to ... to,completion of the transaction. As presently contemplated, a ...
... /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX), a leading ... outsourcing company with operations in China and ... has won the 2008 Frost & Sullivan,Award ... Pharmaceuticals and,Biotechnology., (Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO ...
Cached Biology Technology:Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission 2Vermillion to Host Live Roundtable Discussion With Principal Investigator of OVA1(TM) Submission 3Signalife Board Approves Merger 2Signalife Board Approves Merger 3WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology 2WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology 3
(Date:12/4/2014)... Dec. 3, 2014  Crossmatch™, a leading provider ... its DigitalPersona ® Pro Enterprise software and ... deployed throughout First Bank branch locations in ... Carolina and Virginia. First Bank, a progressive ... Pines, North Carolina , selected the Crossmatch ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014 Strict ... driver efficiency are piloting the North American and European ... of accidents growing, gesture recognition systems that are intuitive ... a mark in the industry. New ... Automotive Gesture Recognition Market in Europe ...
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that seven officials ... least seven more will participate in the upcoming 2014 PDA ... Washington D.C. , Dec. 2-4. ... the regulatory agencies in the United States ... to help advance the use of metrics in the regulatory ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... available in French . , A study ... differences between individuals at the DNA level can lead ... These, in turn, are responsible for the vast array ... part of the Genome Regulators in Disease (GRID) Project ...
... the Tenovus Centre for Cancer Research at Cardiff University ... could help save the lives of women who become ... While drugs such as tamoxifen have been a huge ... of sufferers the drugs either fail to work, or ...
... Colloquium series will hold a meeting on gene ... program for the development of animal embryos, body ... focus on four areas -- gene regulatory networks ... developmental processes; regulatory processes in complex multigenic systems; ...
Cached Biology News:Tiny genetic differences have huge consequences: McGill researchers 2Further breakthroughs for breast cancer patients 2
The Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: 6 microcentrifuge tubes....
No description available in Ensembl Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
No description available in Ensembl. Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
12(S)-HETE-d8 is used as an internal standard for the quantification of 12(S)-HETE by stable isotope dilution mass spectrometry....
Biology Products: